Just a quick refresher course in cancer markers from Dr Moro (and why I never waivered in my belief in this technology):
An advantage of RECAF is that it's found in not only the tissue of cancer patients so biopsies can be examined, but also in the bloodstream so that a simple blood test can be used to detect cancer.
"Having the ability to find the marker in the bloodstream is a tremendous advantage over doing a biopsy," states Dr. Moro-Vidal. "It's simple, it's efficient, and it can be applied to some of the most common types of cancer for which there are no other useful markers."
We are a niche company. We can identify cancer without a biopsy (huge benefit to patient, insurance, and the entire healthcare system). We can MONITOR if cancer has returned, we can detect cancer early, and we can eliminate false positives with current cancer-specific markers.
I am not even talking about the different methods Dr Moro has developed to detect cancer utilizing recaf. Don't forget that recaf "lights up" the cancer when we attach a radioisotope making it visible and creates an image that shows where cancer is present. Men have a one in two lifetime risk of developing cancer, while women have a one in three lifetime risk. With cancer that prevalent, Biocurex has a very bright future. After the shareholder meeting and we hopefully get confirmation by the shareholders we will be on our way. Dr Moro will finally be able to execute his plan. The oncopet site will be up and running and we will initially be testing for vets in our lab $$$$$$$$$.
